Essity B stock gains attention after Edgewell deal closes

Published on 09/17/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Essity B stock is in focus as Edgewell Personal Care completed the sale of its Feminine Care segment to Essity for about USD 340 million after quarter-end, as of September 17, 2026. The transaction reshapes Essity’s hygiene portfolio while valuation debates continue around its Consumer Tissue unit.

Essity AB SE0009922164: Fabrikhalle mit Hygienepapierrollen und Personal — Essity AB (ISIN SE0009922164) betreibt moderne Fabriken zur Herstellung von Hygiene- und Papierprodukten weltweit heute, Illustration mit AI erstellt.

Essity B stock (ISIN SE0009922164) is drawing renewed attention as Edgewell Personal Care has completed the sale of its Feminine Care segment to Essity for approximately USD 340 million in cash, a portfolio move that investors are reassessing as of September 17, 2026.

Edgewell Feminine Care acquisition reshapes Essity

According to StockTitan, Edgewell reported closing the sale of its Feminine Care segment, including the Playtex, Stayfree, Carefree and o.b. brands, to Essity for about USD 340 million on a cash-free, debt-free basis after the end of its fiscal second quarter 2026.

As StockTitan reports, Edgewell recorded a goodwill impairment of USD 37.4 million and a USD 2.2 million loss on assets held for sale associated with the transaction, underlining how strategically significant the Feminine Care business is for both companies.

Valuation debate around Consumer Tissue

Beyond the Edgewell deal, Essity’s portfolio strategy is also being discussed in the context of a possible separation of its Consumer Tissue business. Swedish business weekly Affarsvarlden recently commented on an indicative valuation range of EUR 2.5 billion to EUR 3.0 billion for Essity’s Consumer Tissue unit, noting that this implies that the remaining operations would be valued at around 12 to 13 times EV/EBIT, assuming the business continues to develop in line with consensus expectations, according to Placera on September 16, 2026.

The indicated EUR 2.5 billion to EUR 3.0 billion price tag for Consumer Tissue, combined with the USD 340 million Feminine Care acquisition, illustrates how Essity is actively reshaping its mix between tissue, personal care and professional hygiene products. For investors, the implied 12 to 13 times EV/EBIT multiple provides a quantified comparison point against other European hygiene and consumer-goods peers, as highlighted by Placera.

Stock and valuation perspective

The closing of the Feminine Care acquisition for about USD 340 million as reported in Edgewell’s second-quarter fiscal 2026 filings, together with the EUR 2.5 billion to EUR 3.0 billion indicative valuation for Consumer Tissue, gives Essity a clearer financial framework for its capital allocation and future portfolio moves, according to StockTitan and Placera.

For shareholders, the combination of a cash-funded acquisition and a possible Consumer Tissue separation means Essity’s leverage, margins and earnings mix could evolve notably over the next reporting periods. The Edgewell Feminine Care purchase adds roughly USD 340 million of enterprise value at transaction price, while the Consumer Tissue indication of EUR 2.5 billion to EUR 3.0 billion suggests that a partial or full sale would release substantial capital compared with Essity’s current EV/EBIT valuation band as described by Placera.

Essity B stock price and market data

Essity B shares are primarily listed on Nasdaq Stockholm in Swedish krona; price data as of the latest completed trading day around September 17, 2026, show the stock trading on its home exchange with a market capitalization in the large-cap range and a typical daily volume in the hundreds of thousands of shares, reflecting the company’s role as a core Nordic hygiene and tissue producer.